Aclaris Therapeutics Inc (NASDAQ:ACRS) — Market Cap & Net Worth
Market Cap & Net Worth: Aclaris Therapeutics Inc (ACRS)
Aclaris Therapeutics Inc (NASDAQ:ACRS) has a market capitalization of $353.21 Million ($353.21 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #14151 globally and #3385 in its home market, demonstrating a -2.88% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Aclaris Therapeutics Inc's stock price $5.40 by its total outstanding shares 108345239 (108.35 Million). Also see ACRS total asset value for a full breakdown of the balance sheet.
Aclaris Therapeutics Inc Market Cap History: 2015 to 2026
Aclaris Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows change from $2.92 Billion to $585.06 Million (-9.16% CAGR). Also see ACRS cash generation efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
Aclaris Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.01% | #384 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #1380 of 3165 |
Weight: Aclaris Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Aclaris Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Aclaris Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Aclaris Therapeutics Inc share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
14.35x
Aclaris Therapeutics Inc's market cap is 14.35 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $2.67 Billion | $1.68 Million | -$68.52 Million | 1587.52x | N/A |
| 2018 | $800.67 Million | $10.09 Million | -$132.74 Million | 79.35x | N/A |
| 2019 | $204.77 Million | $4.23 Million | -$161.35 Million | 48.44x | N/A |
| 2020 | $700.99 Million | $6.48 Million | -$51.15 Million | 108.14x | N/A |
| 2021 | $1.58 Billion | $6.76 Million | -$90.86 Million | 233.00x | N/A |
| 2022 | $1.71 Billion | $29.75 Million | -$86.91 Million | 57.36x | N/A |
| 2023 | $113.76 Million | $31.25 Million | -$88.48 Million | 3.64x | N/A |
| 2024 | $268.70 Million | $18.72 Million | -$132.06 Million | 14.35x | N/A |
Competitor Companies of ACRS by Market Capitalization
Companies near Aclaris Therapeutics Inc in the global market cap rankings as of September 18, 2026. Review tangible equity quality of Aclaris Therapeutics Inc to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Aclaris Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Aclaris Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Aclaris Therapeutics Inc's market cap moved from $2.92 Billion to $ 585.06 Million, with a yearly change of -9.16%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $585.06 Million | +79.40% |
| 2025 | $326.12 Million | +21.37% |
| 2024 | $268.70 Million | +136.19% |
| 2023 | $113.76 Million | -93.33% |
| 2022 | $1.71 Billion | +8.32% |
| 2021 | $1.58 Billion | +124.73% |
| 2020 | $700.99 Million | +242.33% |
| 2019 | $204.77 Million | -74.42% |
| 2018 | $800.67 Million | -70.03% |
| 2017 | $2.67 Billion | -9.14% |
| 2016 | $2.94 Billion | +0.74% |
| 2015 | $2.92 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Aclaris Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $353.21 Million USD |
| MoneyControl | $353.21 Million USD |
| MarketWatch | $353.21 Million USD |
| marketcap.company | $353.21 Million USD |
| Reuters | $353.21 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Aclaris Therapeutics Inc
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its … Read more